Palma Fedele

13PUBLICATIONS
12CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jul 10, 2026
Early first-line systemic anticancer therapeutic attrition after metastatic recurrence in triple-negative breast cancer following neoadjuvant chemo-immunotherapy: a multicenter real-world study.

|Dec 30, 2025
BRCA1 and 2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter Analysis.

Palma Fedele, Alessandro Rizzo, Matteo Landriscina

|Nov 13, 2025
Impact of Chemotherapy Dose Intensity on Pathological Complete Response in Pembrolizumab-Treated Early Triple-Negative Breast Cancer: A Real-World Multicenter Analysis.

Palma Fedele, Stefania Luigia Stucci, Matteo Landriscina

|Oct 29, 2025
CDK4/6 Inhibitors in Patients Aged 80 and Older with HR+/HER2- Metastatic Breast Cancer: A Real-World Multicenter Study.

Palma Fedele, Matteo Landriscina, Lucia Moraca

|Dec 17, 2024
Standard Versus Reduced CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: An Observational Multicenter Study.

Palma Fedele, Matteo Landriscina, Lucia Moraca

|Dec 17, 2024
Predictive Factors of Antibody-Drug Conjugate Treatment in Metastatic Breast Cancer: A Narrative Review.

Gennaro Gadaleta-Caldarola, Laura Lanotte, Anna Natalizia Santoro

Pageof 3

Frequent Collaborators

4 joint publications

Matteo Landriscina

3 joint publications

Carmelo Laface

3 joint publications

Marianna Giampaglia

3 joint publications

Gennaro Gadaleta-Caldarola